| Literature DB >> 20811491 |
Gordon Mansergh1, Beryl A Koblin, David J McKirnan, Sharon M Hudson, Stephen A Flores, Ryan E Wiegand, David W Purcell, Grant N Colfax.
Abstract
BACKGROUND: Substance use during sex is associated with sexual risk behavior among men who have sex with men (MSM), and MSM continue to be the group at highest risk for incident HIV in the United States. The objective of this study is to test the efficacy of a group-based, cognitive-behavioral intervention to reduce risk behavior of substance-using MSM, compared to a randomized attention-control group and a nonrandomized standard HIV-testing group. METHODS ANDEntities:
Mesh:
Year: 2010 PMID: 20811491 PMCID: PMC2927550 DOI: 10.1371/journal.pmed.1000329
Source DB: PubMed Journal: PLoS Med ISSN: 1549-1277 Impact factor: 11.069
Project MIX, baseline characteristics and bivariate comparisons, by group, 2004–2008.
| Characteristic | Intervention ( | Attention Control ( | Standard ( | |
|
|
|
| ||
| Age group (y) | 18–24 | 70 (12) | 56 (9) | 64 (13) |
| 25–34 | 158 (26) | 162 (27) | 150 (31) | |
| 35–44 | 239 (40) | 265 (44) | 168 (35) | |
| ≤45 | 132 (22) | 124 (20) | 98 (21) | |
| Primary race/ethnicity | Black | 200 (33) | 194 (32) | 124 (26) |
| Hispanic/Latino | 120 (20) | 102 (17) | 97 (20) | |
| White | 225 (38) | 241 (40) | 216 (45) | |
| Other | 54 (9) | 70 (11) | 43 (9) | |
| Education level | ≤High school diploma | 190 (32) | 191 (31) | 111 (23) |
| >High school education | 198 (33) | 216 (36) | 179 (37) | |
| ≥College degree | 211 (35) | 200 (33) | 190 (40) | |
| HIV serostatus | Positive | 307 (51) | 300 (49) | 178 (37) |
| Negative | 248 (42) | 272 (45) | 245 (51) | |
| Unknown | 44 (7) | 35 (6) | 57 (12) | |
| Sexual orientation identification | Gay/homosexual | 501 (84) | 508 (84) | 410 (85) |
| Bisexual/other | 98 (16) | 99 (16) | 70 (15) | |
| City | Chicago | 159 (27) | 160 (26) | 150 (31) |
| Los Angeles | 118 (20) | 118 (20) | 99 (21) | |
| New York | 151 (25) | 159 (26) | 102 (21) | |
| San Francisco | 171 (28) | 170 (28) | 129 (27) | |
Standard group significantly different from intervention and attention-control groups (chi-square test, p<0.05); other overall 3-way tests were nonsignificant (p>0.05).
Figure 1CONSORT flow diagrams.
(A) October 2004–April 2008 (screen through 3, 6, and 12-mo follow-up): randomized intervention and attention-control groups. (B) December 2006–September 2007 (screen through 3-mo follow-up): nonrandomized standard control group.
Project MIX primary and secondary outcome behaviors, by group at assessment wave, 2004–2008.
| Behavior Soon Before or During Most Recent Anal Sex Encounter | Baseline (%) | 3 mo (%) | 6 mo (%) | 12 mo (%) | ||||||
| Interv ( | Attn ( | Stand ( | Interv ( | Attn ( | Stand ( | Interv ( | Attn ( | Interv ( | Attn ( | |
|
| ||||||||||
| UA | 67 | 68 | 68 | 43 | 44 | 43 | 43 | 42 | 40 | 38 |
| DUA | 39 | 38 | 43 | 19 | 21 | 23 | 17 | 18 | 18 | 20 |
| Substance use and UA | ||||||||||
| Alcohol | 42 | 40 | 42 | 21 | 21 | 21 | 20 | 21 | 17 | 17 |
| Drugs | 45 | 43 | 39 | 26 | 24 | 22 | 27 | 23 | 22 | 19 |
| Substance use and DUA | ||||||||||
| Alcohol | 27 | 23 | 28 | 10 | 11 | 13 | 8 | 9 | 9 | 10 |
| Drugs | 25 | 24 | 24 | 12 | 12 | 11 | 10 | 9 | 10 | 11 |
|
| ||||||||||
| URA | 38 | 41 | 39 | 24 | 26 | 25 | 23 | 24 | 25 | 22 |
| UIA | 39 | 36 | 35 | 24 | 22 | 21 | 24 | 23 | 20 | 20 |
| Substance use | 77 | 78 | 75 | 54 | 52 | 53 | 52 | 49 | 46 | 44 |
Attn, attention-control group; Interv, intervention group; Stand, standard group; URA, unprotected receptive anal sex; UIA, unprotected insertive anal sex.
Project MIX, multivariate results for outcome behaviors, by group at assessment wave, 2004–2008.
| Group | Primary Outcomes, AOR (CI) | Secondary Outcomes, AOR (CI) | |||||||
| UA | DUA | Alcohol-UA | Drug-UA | Alcohol-DUA | Drug-DUA | URA | UIA | Substance Use during Sex | |
|
| |||||||||
| Attention-control (referent) | |||||||||
| Intervention | 0.95 (0.72–1.26) | 1.06 (0.82–1.38) | 1.15 (0.88–1.50) | 1.07 (0.81–1.42) | 1.25 (0.93–1.67) | 1.04 (0.77–1.40) | 0.85 (0.64–1.13) | 1.15 (0.87–1.52) | 0.96 (0.70–1.30) |
| Follow-up (baseline, referent) | |||||||||
| 3 mo | 0.34 (0.26–0.43) | 0.41 (0.31–0.54) | 0.37 (0.28–0.49) | 0.36 (0.27–0.47) | 0.40 (0.29–0.57) | 0.42 (0.30–0.58) | 0.46 (0.35–0.61) | 0.48 (0.36–0.63) | 0.27 (0.21–0.36) |
| 6 mo | 0.29 (0.23–0.38) | 0.34 (0.25–0.45) | 0.37 (0.28–0.49) | 0.32 (0.24–0.42) | 0.32 (0.23–0.45) | 0.28 (0.19–0.40) | 0.40 (0.30–0.53) | 0.50 (0.37–0.66) | 0.24 (0.18–0.31) |
| 12 mo | 0.24 (0.18–0.31) | 0.37 (0.28–0.49) | 0.27 (0.20–0.36) | 0.25 (0.18–0.33) | 0.34 (0.24–0.48) | 0.33 (0.24–0.47) | 0.33 (0.25–0.43) | 0.40 (0.31–0.54) | 0.19 (0.14–0.25) |
| Intervention group comparisons | |||||||||
| Baseline—Interv (versus Attn) | 0.95 (0.71–1.27) | 1.06 (0.81–1.39) | 1.15 (0.88–1.51) | 1.07 (0.80–1.43) | 1.25 (0.92–1.69) | 1.04 (0.76–1.41) | 0.85 (0.63–1.14) | 1.15 (0.86–1.53) | 0.96 (0.69–1.32) |
| 3 mo—Interv (versus Attn) | 0.93 (0.70–1.22) | 0.89 (0.64–1.23) | 0.99 (0.72–1.37) | 1.06 (0.77–1.46) | 0.88 (0.58–1.32) | 0.92 (0.62–1.37) | 0.86 (0.63–1.19) | 1.11 (0.81–1.53) | 1.13 (0.85–1.49) |
| 6 mo—Interv (versus Attn) | 1.01 (0.76–1.33) | 0.89 (0.64–1.25) | 0.94 (0.68–1.30) | 1.26 (0.91–1.75) | 0.87 (0.56–1.35) | 1.14 (0.74–1.76) | 0.94 (0.67–1.30) | 1.03 (0.75–1.42) | 1.12 (0.85–1.49) |
| 12-mo—Interv (versus Attn) | 1.14 (0.86–1.51) | 0.92 (0.66–1.28) | 1.06 (0.75–1.49) | 1.21 (0.86–1.70) | 0.86 (0.56–1.32) | 0.98 (0.64–1.48) | 1.27 (0.91–1.77) | 1.05 (0.75–1.47) | 1.10 (0.83–1.45) |
|
| |||||||||
| Standard (referent) | |||||||||
| Intervention | 0.93 (0.71–1.23) | 0.87 (0.67–1.13) | 1.00 (0.77–1.31) | 1.13 (0.86–1.48) | 0.97 (0.73–1.30) | 1.00 (0.74–1.36) | 0.84 (0.64–1.12) | 1.17 (0.89–1.54) | 1.04 (0.77–1.40) |
| Attention-control | 0.97 (0.74–1.28) | 0.84 (0.64–1.09) | 0.88 (0.68–1.15) | 1.05 (0.80–1.38) | 0.80 (0.59–1.07) | 0.97 (0.71–1.31) | 0.98 (0.74–1.30) | 1.03 (0.78–1.35) | 1.09 (0.81–1.48) |
| Follow-up (baseline, referent) | |||||||||
| 3-mo | 0.34 (0.26–0.45) | 0.39 (0.29–0.53) | 0.35 (0.26–0.47) | 0.39 (0.29–0.53) | 0.35 (0.25–0.5) | 0.39 (0.27–0.57) | 0.52 (0.37–0.72) | 0.50 (0.36–0.69) | 0.37 (0.27–0.49) |
| Intervention group comparisons | |||||||||
| Baseline—Interv (versus Attn) | 0.96 (0.73–1.26) | 1.05 (0.81–1.35) | 1.14 (0.88–1.47) | 1.07 (0.82–1.39) | 1.22 (0.91–1.62) | 1.04 (0.77–1.39) | 0.86 (0.65–1.13) | 1.14 (0.88–1.49) | 0.95 (0.70–1.28) |
| Baseline—Interv (versus Stand) | 0.93 (0.70–1.24) | 0.87 (0.67–1.14) | 1.00 (0.77–1.32) | 1.13 (0.85–1.50) | 0.97 (0.72–1.31) | 1.00 (0.73–1.37) | 0.84 (0.63–1.13) | 1.17 (0.88–1.56) | 1.04 (0.76–1.42) |
| Baseline—Attn (versus Stand) | 0.97 (0.73–1.30) | 0.84 (0.64–1.09) | 0.88 (0.67–1.16) | 1.05 (0.79–1.39) | 0.80 (0.59–1.08) | 0.97 (0.70–1.32) | 0.98 (0.74–1.32) | 1.03 (0.77–1.37) | 1.09 (0.80–1.50) |
| 3 mo—Interv (versus Attn) | 0.95 (0.73–1.23) | 0.88 (0.65–1.20) | 1.00 (0.74–1.36) | 1.06 (0.79–1.42) | 0.86 (0.58–1.27) | 0.93 (0.64–1.36) | 0.88 (0.65–1.19) | 1.15 (0.85–1.54) | 1.12 (0.87–1.45) |
| 3 mo—Interv (versus Stand) | 0.95 (0.72–1.25) | 0.78 (0.57–1.08) | 0.98 (0.71–1.36) | 1.09 (0.79–1.51) | 0.79 (0.53–1.19) | 0.96 (0.63–1.45) | 0.80 (0.58–1.11) | 1.18 (0.86–1.63) | 0.98 (0.74–1.29) |
| 3 mo—Attn (versus Stand) | 0.99 (0.75–1.31) | 0.89 (0.65–1.22) | 0.98 (0.71–1.36) | 1.03 (0.74–1.43) | 0.93 (0.62–1.38) | 1.03 (0.69–1.55) | 0.91 (0.66–1.26) | 1.03 (0.75–1.42) | 0.87 (0.67–1.15) |
Controlled for all variables listed plus city, age, race/ethnicity, education level, sexual orientation identification, and HIV serostatus.
AOR, adjusted odds ratio; Attn, attention-control group; Interv, intervention group; Stand, standard of care group; UIA, unprotected insertive anal sex; URA, unprotected receptive anal sex.
Substance use soon before or during most recent anal sex encounter.